INTRODUCTION: Topical tretinoin is considered the gold standard to treat 
photoaged skin, but it is associated with side effects and only available upon 
prescription.
AIM OF THE STUDY: To compare the efficacy, tolerance, and perception of a fixed 
proprietary combination (Retinol 0.2%/LR2412 2%) vs. tretinoin 0.025% cream in 
women with photoaged skin.
MATERIAL/METHODS: In this randomized, parallel, double-blind, controlled 
clinical study, women applied to the entire face for 3 months in the morning a 
SPF 50 sunscreen and in the evening either the association of Retinol 
0.2%/LR2412 2% or tretinoin 0.025%. Clinical and instrumental parameters were 
assessed at days 0, 28, 56, and 84. Subject perception of the efficacy, 
tolerance and cosmeticity of the tested products were assessed at days 28, 56, 
and 84.
RESULTS: A total of 120 women (60 to Retinol 0.2%/LR2412 2% cream and 60 to 
tretinoin 0.025% cream) were included in the study. Both products improved 
considerably wrinkles, mottled pigmentation, pores, and global photodamage. No 
statistically significant differences were noted between Retinol 0.2%/LR2412 2% 
cream and tretinoin 0.025% cream. Adverse effects were mostly graded mild. 
Overall, Retinol 0.2%/LR2412 2% cream was better tolerated than tretinoin 0.025% 
cream. At all visits, subject perception of the association of Retinol 
0.2%/LR2412 2% was either comparable to or better than tretinoin 0.025% cream.
CONCLUSION: The treatment outcome of Retinol 0.2%/LR2412 2% cream does not 
differ from the one of tretinoin 0.025% cream. Clinical results were not 
statistically different. Furthermore, Retinol 0.2%/LR2412 2% cream is better 
tolerated and better perceived by women used to rejuvenation procedures.